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Background: Patients diagnosed for a serous ovarian borderline tumor (s-BOT) typically present with an excellent
clinical outcome. However there have been controversies concerning the prognostic impact of so-called implants,
an extra ovarian spread occurring alongside the s-BOT in certain cases. It remains obscure whether these implants
actually resemble metastasis owning the same genetic pattern as the ovarian primary or whether they develop
independently.
Methods: The current study, in the aim of further clarifying the genetic origin of implants, assessed BRAF/KRAS hot
spot mutations and the p53/p16INK4a immunophenotype of s-BOTs and corresponding implants (n = 49) of 15
patients by pyro-sequencing and immunostaining, respectively.
Results: A significant proportion of both s-BOTs and implants showed KRAS or BRAF mutation and though p16INK4a
was found to be abundantly expressed, p53 immunoreactivity was rather low. When genotypes of BRAF/KRAS
mutated s-BOTs and corresponding implants were compared no patient presented with a fully matching mutation
profile of s-BOTs and all corresponding implants.
Conclusions: The current study reveals genetic heterogeneity of s-BOTs and implants, as none of the markers
examined showed constant reciprocity. Hence, our findings may assist to explain the different clinical presentation
of s-BOTs and implants and might encourage to applying more individualized follow up protocols.
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Serous ovarian borderline tumors (s-BOTs) and advanced
stage invasive ovarian cancer (IOC) differ regarding mor-
phological, clinical and molecular characteristics. s-BOTs
show an atypical degree of proliferation lacking obvious
stromal invasion [1]. According to the Malpica grading
system s-BOTs may be associated with low-grade IOC [2],
while high grade IOCs show marked nuclear atypia and
mitotic activity [2].
Usually s-BOTs are characterized by their excellent
clinical outcome as compared to advanced stage IOC
[3,4]. Though, it needs to be noted that, in contrast to* Correspondence: doris.mayr@med.uni-muenchen.de
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reproduction in any medium, provided the orIOC, s-BOTs frequently affect younger patients and
might, in certain rare but not insignificant cases, also
progress into low grade IOC [1,5]. Since it remains chal-
lenging to identify patients at risk, it has been discussed
repeatedly, to which extent so called implants, representing
extra-ovarian lesions coincidentally occurring in about
20% of particularly serous s-BOT cases, influence patients’
prognosis [1,4,6]. While it is broadly accepted that im-
plants presenting with invasive features are of adverse
prognostic significance [7-9], the impact of non-invasive
implants is less clear. As stated by the WHO non-invasive
implants have no to little effect on patients’ outcome,
while invasive implants are associated with increased re-
currence rates and a significantly reduced 10 year survival
[10]. Hence it is critical to further investigate implant
pathophysiology and genetic origin.al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Heublein et al. BMC Cancer 2013, 13:483 Page 2 of 9
http://www.biomedcentral.com/1471-2407/13/483It remains to be elusive whether implants actually arise
independently alongside the ovarian s-BOT as part of a
field effect, or whether they may directly develop from
the ovarian primary resembling its metastasis. Within
the first scenario implants are supposed to be of heteroge-
neous origin and thus comprise a different genetic pattern
as compared to the ovarian tumor while metastases are
postulated to rise in a clonal manner and thus should
closely mimic their primary. In general, since clonality of
neoplastic lesions is discussed to be of prognostic signifi-
cance, determining the mutation status of s-BOTand their
corresponding implants may turn out to be of clinical use.
To address this question, this study employed pyro-
sequencing of KRAS (Kirsten rat sarcoma viral oncogene
homolog) and BRAF (v-raf murine sarcoma viral oncogene
homolog B1) hot spot regions in s-BOTs and correspond-
ing implants. Since both KRAS and BRAF are known to
be frequently mutated in s-BOTs [11], they are espe-
cially suitable to indicate a possible genetic descent of
extraovarian implants in s-BOT patients. BRAF and
KRAS are upstream activators of the mitogen-activated
protein kinase (MAPK) cascade which is commonly
hyper-activated in different types of human cancer [12].
Further, p16INK4a (p16) and p53 immunoreactivity of
s-BOTs and associated implants was compared. p16 acts
as a cell cycle inhibitor antagonizing MAPK signaling and
is compensatory up-regulated under hyper-proliferative
conditions including high risk human papilloma virus
infection or oncogene activation [13-15]. Accumulation of
the tumor suppressor protein p53 was observed in
malignant cells [16] thus leading to the assumption that
mutation in TP53 may cause overexpression of p53
protein [16,17]. Up to now the mechanism leading to
p53 up-regulation remains to be controversial [17].
Today, assessing p53 by immunohistochemistry instead
of TP53 mutation analysis is a well-established method
[18-21] and has been intensively studied [22,23]. How-
ever, it needs to be mentioned that so far p53 immuno-
histochemistry may not fully resemble TP53 mutation
testing. Though high grade IOC is characterized by p53
overexpression, the latter is considered a seldom event
in both low grade IOC [24,25] and in s-BOTs [26]. We
included both p16 and p53 immunohistochemistry
in order to investigate whether these markers might
be useful to match implants and their corresponding
s-BOT(s).
Ultimately, our goal was to clarify whether implants
actually resemble the mutation (regarding KRAS and
BRAF) or protein expression (regarding p16 and p53)
profile of corresponding s-BOTs. Further insights on
origin and genetic causes of both s-BOTs and corre-
sponding implants may help to identify patient sub-
groups that might benefit from more individualized
therapy.Methods
Patients
In total 15 patients (Table 1), that had undergone
surgery at the Department of Obstetrics and Gynecology
of the Ludwig-Maximilians-University of Munich due to a
suspected ovarian tumor between 2003 and 2009, were in-
cluded in this study. All patients were diagnosed for either
uni (n = 9)- or bilateral (n = 6) s-BOTs and concomitant
implants. One up to 19 implants (total number: n = 49)
were identified in each patient. Patient age at surgery
ranged between 22 and 75 years (median = 46 years).
Histological diagnoses according to the FIGO criteria were
conducted at the Department of Pathology of the Ludwig-
Maximilians-University of Munich by two experienced
gynecological pathologists. All tumors were of serous hist-
ology and were staged analogically to invasive carcinomas
of the ovary. Five patients were classified as FIGO II, while
the remaining 10 patients were staged as FIGO III.
All implants were non-invasive according to the
WHO criteria and presented with serous histology. In
four cases the patient had one implant, in six cases two
and in the remaining cases three or more. Differenti-
ation between non-invasive and invasive implants was
performed according to criteria of the WHO [10] by
two experienced gynecological pathologists at the
Department of Pathology of the Ludwig-Maximilians-
University of Munich. According to the WHO, the diag-
nosis of non-invasive implants was performed when they
were typically localized on the surface, in submesothelial
spaces or with extension into interlobular fibrous septa
without infiltration of the underlying tissue. In contrast,
diagnosis of invasive implants was made when the lesions
disorderly infiltrated the normal tissue with irregular
borders and showed nuclei resembling cells of low-grade
serous adenocarcinoma.
Follow up data of all patients were available and re-
trieved from the Munich tumor registry. As of September
2013 three patients from the cohort had already died at
the age of 78 years, 75 years and 73 years. Since just one
of these deaths was reported as being cancer related, the
remaining two cases were excluded from survival analysis.
Mean follow up was 4.8 years (95% CI = 3.5 years - 6.2
years) and the only cancer related death was observed in a
woman that died at the age of 78 (2.6 years after surgery).
Ethics statement
The study was approved by the ethics committee of the
LMU of Munich. Patients’ data and samples were
anonymized and processed in compliance with the
guidelines of the Helsinki Declaration of 1975.
Immunohistochemistry (IHC)
Sections of standard paraffin-embedded tissue were
stained for p53 (ThermoScientific, Munich, Germany
Table 1 Genotypes of s-BOTs and corresponding implants
s-BOT(s) Implant(s)
Patient KRAS BRAF Implants (n) Mutation profiles (n) KRAS BRAF
1 Unilateral wt wt 1 1 wt wt
2 Bilateral wt p.V600E 4 3 wt wt
1 wt p.V600Ewt p.V600E
3 Unilateral p.G12D wt 1 1 p.G12D p.V600E
4 Unilateral wt wt 4 4 wt wt
5 Bilateral wt p.V600E 2 1 wt wt
1 p.G12D wtwt p.V600E
6 Unilateral wt p.V600E 2 1 wt wt
1 wt p.V600E
7 Unilateral wt wt 3 3 wt wt
8 Bilateral wt wt 2 2 wt wt
wt wt
9 Unilateral wt p.V600E 2 1 wt p.V600E
1 wt wt
10 Unilateral p.G12A p.V600E 1 1 wt p.V600E
11 Bilateral wt p.V600E 2 1 p.G12V p.V600E
1 wt p.V600Ep.G12V wt
12 Bilateral p.G12A p.V600E 3 1 p.G12A p.V600E
2 wt p.V600Ep.G12A p.V600E
13 Unilateral wt wt 2 2 wt p.V600E
14 Unilateral p.G12V wt 1 1 wt p.V600E
15 Bilateral p.G12V p.V600E 19 11 p.G12V wt
1 wt p.V600E
p.G12V wt 1 p.G12V p.V600E
6 wt wt
n.a. = not applicable. The total number of implants diagnosed in each patient is displayed in the “number of implants” column and the count of how often each
mutation profile was observed is specified in the “mutation profiles” column.
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using Ventana Benchmark® XT (Roche) in an automatic
manner. The signal was quantified using a semi quanti-
tative method [27] by two independent observers by
consensus. At a glance the immuno-reactive (IR)-score
quantifies intensity (1 = low, 2 = moderate, 3 = strong)
and percentage of stained cells (0 = no, 1 = less than
10%, 2 = 10%-50%, 3 = 51%-80%, 4 = 81%-100%). Multi-
plication of these scores results in the IR-score ranging
from 0 to 12. In this study the IR-score was subdivided
as follows: IRS = 0, IRS = 1, IRS = 2 - negative; IRS = 3,
IRS = 4 - weakly positive; IRS = 6, IRS = 8 - moderately
positive; IRS = 9, IRS = 12 - strongly positive.
KRAS/BRAF pyrosequencing
Hot spot mutations in KRAS exon 2 and BRAF exon 15
were analyzed. For each s-BOT/implant sequencing ana-
lysis of KRAS and BRAF was done on the same anatomic-
ally micro-dissected tumor/implant sample. KRAS/BRAFgenotyping was performed by PCR and direct sequencing
in a German reference laboratory for KRAS mutation
testing (Department of Pathology, LMU of Munich). All
tumors/implants underwent micro-dissection, followed by
DNA isolation using DNA Micro-Amp-kits (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol.
Mutation testing in codons 12 and 13 of the KRAS
proto-oncogene was done by pyrosequencing employing
Qiagen’s PyroMark GoldVR kits together with a Q24
pyrosequencer device (Qiagen). This procedure was
used to detect mutations in the KRAS proto-oncogene
with a specificity of 0.98 and sensitivity of 0.99 [28,29].
Following DNA isolation BRAF exon 15 was amplified
[PCR buffer, 1.5 mM MgCl2, 200 nM dNTPs, 400 nM
primers, 1 U Hotstar Taq-polymerase (Qiagen)] using the
following primers: forward 5’-TGAAGACCTCACAGTAA
AAATAGG-3’, reverse 5’- TCCAGACAACTGTTCAAAC
TGAT-3’. PCR products were processed using Pyro-Gold
kits (Qiagen) together with 3 nM of the corresponding
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(Qiagen). The PyroMark™-Q24 software (Qiagen) was
used for data analysis.Statistical analysis
For all statistical calculations Superior Performance
Software System 19 was used. Wilcoxon Signed Ranks
Test, Mann–Whitney U Test and the Spearman correl-
ation coefficient were employed to analyze data. Values
are displayed in terms of mean ± standard error and
p-values lower than 0.05 were considered as statisti-
cally significant.Results
p53 and p16 in s-BOTs and implants
None of the s-BOT samples examined was rated as highly
(IRS > 8) positive for p53. Less than half of all patients
were found to carry at least one s-BOT rated as either
weakly (n = 5; 5/15; 33.3%) or moderately (n = 2; 2/15;
13.3%) positive for p53 and in eight (8/15; 53.3%) cases
p53 was not detected at all. In contrast, p16 was abun-
dantly expressed with the majority of patients showing
up to strong (n = 4; 4/15; 26.7%), up to moderate (n = 5;
5/15; 33.3%) or at least weak (n = 4; 4/15; 26.7%) p16
positivity. Consequently, the overall immunoreactivity level
for p16 was significantly higher (mean IRS = 6.0 ± 0.8 vs.
mean IRS = 2.5 ± 0.4; p = 0.001) than for p53. Immunore-
activity of p53 and p16 (Figure 1) did not correlate and
none of the both was significantly associated with clinical
tumor staging.Figure 1 Representative microphotographs of immuno-histochemi
A, A’, C, C’: serous ovarian borderline tumor (s-BOT); B, B’, D, D’: implant
apply to A-D/A’-D’.Immunohistochemical analysis of p53 in implants
(Figure 1) revealed strong p53 positivity in one (1/49;
2.0%), moderate in another one (1/49; 2.0%) and weak
in nine (9/49; 18.4%) implant samples. In terms of
patients, only one patient was identified with an implant
strongly expressing p53. This patient (#3 in Table 1,
Additional file 1) presented with an implant also strongly
expressing p16. Further this implant was found to carry
both KRAS p.G12D and BRAF p.V600E at the same time.
Moreover another seven patients showed either up to
moderate (one patient with moderate p53 expression in
one implant) or up to weak (six patients with at least one
weakly stained implant in each patient) positivity for
p53, respectively. No p53 positive implant at all could
be identified in the remaining seven cases. Yet again
overall immunoreactivity for p53 was significantly lower
than for p16 (mean IRS = 1.7 ± 0.3 vs. mean IRS = 5.4 ±
0.6; p < 0.001), though regarding implants expression of
the two correlated (p = 0.032). About one third (15/49;
30.6%) of implants was found to be negative for p16.
Twelve implants were weakly positive (12/49; 24.5%) for
p16, while 22 (22/49; 44.9%) implant samples were identi-
fied as highly or moderately expressing p16, respectively.
In respect to patients, nine (9/15; 60.0%) of them were
diagnosed with at least one implant overexpressing p16.
KRAS/BRAF genotypes in s-BOTs and implants
KRAS/BRAF genotypes were determined by pyrose-
quencing in s-BOTs and implants (Figure 2). Regarding
the ovarian primary the BRAF variant p.V600E was ob-
served in at least one ovary of about half of all patientscal p53 (A, A’, B, B’) and p16 (C, C’, D, D’) staining are shown.
s associated with s-BOT(s). Scale bars in A/A’ equal 100 μm and
Figure 2 Representative pyro-sequencing mutation analysis results are shown. The BRAF wildtype allele (A) is frequently mutated
(B; p.V600E) in s-BOTs and implants. An amino acid substitution at codon 12 in KRAS (D; p.G12A) alters wildtype KRAS (C).
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p.G12A) were detected in six patients (6/15; 40.0%;
Table 1). Just one patient with a bilateral s-BOT did not
show either KRAS or BRAF mutation. A combined KRAS-
BRAF mutation in the same s-BOT was detected in three
patients (3/15; 20.0%) while another patient was identified
with single KRAS p.G12V in the s-BOT of the left ovary
and single BRAF p.V600E in the s-BOT of the right ovary.
BRAF or KRAS mutated tumors were not significantly
different in respect to their p53, p16 immunophenotype.
Moreover, no relation of KRAS or BRAF mutation and
clinical tumor stage was observed.
When implants were analyzed, about one third (16/49,
32.7%) of all implant samples presented a single point
mutation in codon 12 of the KRAS gene (p.G12V: 13/49,
26.5%, p.G12D: 2/49, 4.1%, p.G12A: 1/49, 2.0%). The BRAF
sequence variation p.V600E was detected in 15 (15/49,
30.6%) implant samples. Regarding total implant count
(n = 49) a co-existing KRAS and BRAF mutation per sample
was detected in 4 (4/49, 8.2%) implants. BRAF mutated
implants showed a trend (p = 0,057) of higher overall p16 im-
munoreactivity though no such relation was observed for p53.Patient wise five patients (5/15, 33.3%) were found to
carry a KRAS mutation in at least one implant while
BRAF p.V600E was detected in ten (10/15, 66.7%)
patients. A coexisting mutation of KRAS and BRAF was
observed in implants of four (4/15, 26.7%) patients and
four (4/15, 26.7%) presented only without either KRAS
or BRAF aberrations in their implants regarding the
gene loci studied.
Comparison of s-BOTs and corresponding implants
To address the question whether implants are developing
alongside the ovarian primary or whether they directly
spread from there, s-BOTs and their corresponding im-
plants were compared regarding p53, p16 expression and
KRAS, BRAF genotype. By contrasting s-BOT cases and
their implants we found a strong correlation in terms of
mean p16 (p16 [s-BOT] - p16 [implant]: p = 0.006; Table 2)
but not p53 mean immunoreactivity.
Out of the 15 patients examined within this study four
cases were found to show wildtype genotypes regarding
both BRAF and KRAS in their s-BOTs as well as in all
the implants diagnosed in these particular patients.
Table 2 Spearman-correlation of mean p53 and mean





p16-implant (mean IRS) cc .026 .673**
p (2-tailed) ns .006
In case of more than one implant or in case of bilateral s-BOT mean IR-scores
were used to correlate s-BOTs and associated implants. ns = not significant,
cc = correlation coefficient (Spearman’s rho), ** Correlation is significant at
the 0.01 level (2-tailed) and significant results are shown in bold.
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a KRAS mutation of their s-BOTs presented with a
matching KRAS mutation in at least one implant while a
KRAS mutation different from the one found in the s-BOT
was not detected. A complete match of a mutant KRAS
allele in s-BOTs and all implants was just observed in a
single patient that notably had only one implant at all
and did not match regarding the BRAF allele. One pa-
tient in this study carried the KRAS p.G12D allele in an
implant though no KRAS mutation at all was detected
in the corresponding s-BOTs. Vice versa, two patients
presented with a KRAS mutated s-BOT though their
implants only carried the KRAS wildtype allele.
In seven out of eight patients diagnosed with a BRAF
mutated s-BOT the same BRAF mutation was found in
at least one implant. Notably, four of these patients
(BRAF mutated s-BOT and the same BRAF mutation in
at least one implant) also carried implants that were
found to have a BRAF wildtype genotype. In one case
BRAF p.V600E was not detected in any implant, though
BRAF p.V600E was found in the s-BOT of this patient.
The other way round three patients only carried BRAF
mutated implant(s) though the ovarian lesion was homo-
zygous for the wildtype allele.
In conclusion, when genotypes of BRAF/KRAS mutated
s-BOTs and corresponding implants were compared no
patient presented with a fully matching BRAF/KRAS
mutation profile of s-BOTs and all implants observed in
the particular case (Table 1).
Discussion
p53/p16 and its relation to KRAS/BRAF genotype
Advanced stage IOCs are supposed to initiate from
TP53 mutated ovarian surface [30] or fallopian tube
[31] epithelium. As mutation in TP53 may cause its up-
regulation, protein over-expression of p53 is frequently
assessed [18-21]. This study performed immunohisto-
chemistry to determine p53 up-regulation and defined
p53 overexpression for strongly positive (IRS > 8) cases.
Unlike p53, the cell cycle inhibitor p16 is routinely assessed
to sub-classify certain neoplastic lesions. Physiologically,
p16 acts as tumor suppressor inhibiting cell cycle progres-
sion hence attenuating mitogenic effects. Cellular stress
factors like for instance oncogenic activation, as mediatedby HPV infection or constitutive activation of mitogenic
pathways (e.g. KRAS mutation) trigger compensatory p16
up-regulation [13-15]. This study detected a trend of
higher p16 expression in BRAF mutated implants leading
to the conclusion that p16 may act to attenuate BRAF
induced cell cycle progression signals. When s-BOTs and
their corresponding implants were contrasted regarding
KRAS and BRAF mutation status. s-BOTs and implants
correlated in respect of p16 expression. A significant pro-
portion of s-BOTs and implants investigated here were
negative for KRAS and/or BRAF mutation anticipating
that in patients without KRAS or BRAF mutations other
genetic events are likely to contribute to s-BOT develop-
ment and implant formation. Regardless the fact that aber-
rations in KRAS and BRAF had been closely associated
with development and progression of s-BOTs [32-37],
other oncogenic routes, e.g. mutation of p53, being cap-
able to initiate malignant transformation, need to be spec-
ulated for s-BOTs carrying KRAS/BRAF wildtype alleles.
Yet, regarding s-BOTs in this study neither expression of
p53 nor of p16 was significantly altered comparing KRAS/
BRAF mutated vs. wildtype s-BOTs. These findings lead to
the conclusion that even in absence of mutated KRAS/
BRAF, initiation of s-BOTs is not reliant on p53 or may
necessarily alter p16 expression.
Genetic heterogeneity of s-BOTs and associated implants
In contrast to BRAF/KRAS, mutations in TP53 are
reported to be rare in s-BOTs. Comparable to others
[26], this study did not detected strong immunoreactivity
for p53 in any s-BOT case, confirming thus the hypothesis
that s-BOTs and advanced stage IOCs arise via different
genetic pathways. Unexpectedly, herein coexisting BRAF
and KRAS mutations were observed. This finding is un-
likely to be due to sequencing inconsistencies, as the
methods employed to determine BRAF and KRAS muta-
tion status had been intensively validated [28,38,39]. KRAS
mutation analysis was taken out at a German reference
laboratory for KRAS mutation testing at our institute.
Though coexistence of mutations occurring in BRAF or
KRAS has been assumed to be mutually elusive, such phe-
nomena were recently observed in colorectal adenoma/
cancer [40,41] and ovarian malignancies [42,43]. Implant
formation is a relatively seldom event in s-BOT genesis.
However, since just s-BOT patients diagnosed with con-
comitant implants were included in the current study, it is
hard to compare our data to studies mostly reporting on
BOTs in general (regardless of the diagnosis of implants).
A constitutive activation of two directly coupled down-
stream signaling partners in the same pathway is unusual.
This is why we assume that coexisting KRAS, BRAF muta-
tions in the same s-BOT may be indicative for a secondary
genetic event or may reflect a possible polyclonal origin of
s-BOTs and implants.
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to as implants, which present as small nodules mostly lo-
cated on the omentum and peritoneal surfaces. For other
neoplasias such a spread beyond the tumor is termed me-
tastasis, assuming that cells initiating it have originally set-
tled there from the primary tumor. Indeed, it is widely
unknown whether implants actually rise as metastasis of
the primary ovarian neoplasm or whether they rather rep-
resent in situ lesions of extraovarian tissue. The latter hy-
pothesis would presume different, distinct genetic changes
characterizing implants vs. s-BOTs, indicating that they
have developed independently. The current study
addressed this question by comparing s-BOTs and cor-
responding implants regarding genetic alterations asso-
ciated with initiation of ovarian tumors. Since full
penetrance of either KRAS or BRAF aberrations was not
observed in any patient, our data suggest that s-BOTs
and implants develop independently and possibly do
not derive from the same precursor lesion. Most studies
undertaken so far used hyper-methylation analysis to
determine tumor clonality and agree on the finding that
s-BOT and corresponding implants show mono- as well
as polyclonal descent [44,45]. In contrast to IOC [46-48] it
has been suggested earlier that s-BOT are of multifocal
genesis and that associated extraovarian tumors rise in-
dependently [44,45,49]. Accordingly, the present study
strongly supports multifocal origin of s-BOTs and their
associated implants as no fully matching mutation pro-
file among s-BOTs and their corresponding implants
were observed. In order to prove this, we employed
state of the art mutation analysis and immune profiling.
Taking into consideration that clonal descent would
imply the presence of a common genetic pattern, our
data prove that at least some implants may have risen
independently from the ovarian malignancy diagnosed
in the same patient. Statistical association of p16 immuno-
reactivity in implants and the corresponding s-BOT(s)
may reflect the fact that p16 is regulated by external
triggers like for instance virus mediated oncogenic acti-
vation or stimulation of mitogenic pathways [13-15].
These may similarly affect both s-BOTs and implants
hence provoking similar secondary events (e.g. compen-
satory p16 up-regulation) that not necessarily claim to
be linked to s-BOT/implant origin. Since studies on the
genetic descent of implants only employed small patient
numbers, it is imperative to evaluate this topic on a
larger scale in order to validate our conclusions.
Malignant transformation of non-invasive implants and
hence worsening of clinical presentation is a process
depending on time and requires a minimum 10 year
follow up [3,4] period. Due to the fact that the follow
up of the cohort studied herein is relatively short,
statistical survival analysis has not been performed.
Nevertheless our finding that s-BOTs and associatedimplants are heterogeneous lesions may explain a dif-
ferent clinical presentation of s-BOTs and implants
and might encourage to applying more individualized
follow up protocols.
Conclusions
By contrasting BRAF/KRAS genotypes and p53/p16 ex-
pression profiles of s-BOTs and their corresponding
implants this study revealed genetic heterogeneity of the
two. When genotypes of BRAF/KRAS mutated s-BOTs
and corresponding implants were compared, no patient
presented with a fully matching mutation profile of s-BOT
and all corresponding implants, hence hypothesizing that
s-BOTs and implants are not likely to arise from a com-
mon precursor lesion.
Additional file
Additional file 1: Figure S1. A microphotograph of strong immuno-
histochemical p53 staining is shown p53 was found to be strongly
expressed in an implant detected in patient #3. Scale bar equals 100 μm.
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